Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT01765283 Completed - Clinical trials for Urea Cycle Disorders

Safety Study of HepaStem for the Treatment of Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN)

HEP001
Start date: March 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and to appraise the efficacy of one cycle of Hepastem (Heterologous Human Adult Liver-derived Progenitor Cells, HHALPC) infusions in paediatric patients suffering from CN or UCD. The study duration: 12 months starting from the day of treatment: 6 months active surveillance and 6 months observation post-infusion.

NCT ID: NCT01765140 No longer available - Clinical trials for Myasthenic Syndromes, Congenital

Treatment Use of 3,4-Diaminopyridine

Start date: n/a
Phase:
Study type: Expanded Access

This protocol has provided 3,4 diaminopyridine (DAP) under a treatment-use IND to patients with congenital myasthenic syndrome (CMS). It is currently closed to enrollment.

NCT ID: NCT01764711 Completed - Clinical trials for Postural Tachycardia Syndrome

Adrenocorticotropic Hormone Stimulation in Postural Orthostatic Tachycardia Syndrome (POTS)

Start date: January 2013
Phase: N/A
Study type: Interventional

This study is to determine different chemical levels in the blood during a low salt diet. This study will compare normal volunteers to those with Postural Tachycardia Syndrome (POTS)

NCT ID: NCT01764464 Completed - Clinical trials for Post-laminectomy Pain Syndrome

GRASSP: Gralise® for Spine Surgery Pain

GRASSP
Start date: December 2012
Phase: Phase 4
Study type: Interventional

Evaluate the analgesic benefit of Gralise® for post-laminectomy pain syndrome (PLPS)

NCT ID: NCT01763853 Recruiting - Hypovolemia Clinical Trials

Impact of Fluid Resuscitation Therapy on Pulmonary Edema as Measured by Alveolar Fluid Clearance in Patients With Acute Respiratory Distress Syndrome (ARDS)

IROCA
Start date: December 2012
Phase: Phase 4
Study type: Interventional

The need for fluid resuscitation (FR) in ICU patients with acute respiratory distress syndrome (ARDS) is common. Indeed, relative or absolute hypovolemia is a common phenomenon that the intensivist must recognize early and treat promptly. Fluid challenge may have adverse side effects associated with fluid administration. The diffusion within the interstitial space may favor edema formation and cause cardiac dysfunction by volume overload. Edema formation is global and may specifically alter pulmonary alveolar epithelial integrity, leading to enhanced alveolar edema and impaired gas exchange. Currently, two types of fluids are frequently used, crystalloids and colloids. Among colloids and compared to crystalloids, albumin has the theoretical advantage of causing greater volume expansion. We hypothesized that a fluid resuscitation therapy with albumin generates less pulmonary edema than a fluid resuscitation therapy with crystalloids. The aim of our study is to compare alveolar fluid clearance, as a marker of alveolar edema fluid resorption, in 2 groups of patients: those treated with albumin and those treated with crystalloid.

NCT ID: NCT01763580 Completed - Clinical trials for Minimal Change Nephrotic Syndrome (MCNS)

A Study to Evaluate the Effect of Tacrolimus and Corticosteroid Combination Therapy in Patients With Minimal Change Nephrotic Syndrome

T-OPTIMUM
Start date: July 16, 2012
Phase: Phase 4
Study type: Interventional

To compare the therapeutic effect of tacrolimus in combination with low-dose corticosteroid with high-dose corticosteroid alone in patients with minimal-change nephrotic syndrome.

NCT ID: NCT01761825 Enrolling by invitation - Clinical trials for Postural Tachycardia Syndrome

The Effect of Ivabradine on Patients With Postural Tachycardia Syndrome

Start date: December 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether Ivabradine is an effective treatment for postural tachycardia syndrome.

NCT ID: NCT01760668 Completed - Turner Syndrome Clinical Trials

Aortopathy in Persons With Bicuspid Aortic Valve, Turner and Marfan Syndrome

Start date: February 2013
Phase: N/A
Study type: Observational

The study aim is: 1. To examine aortic tissue by light microscopy 2. To examine aortic tissue by electron microscopy 3. To study changes in the epigenome and transcriptome of the X chromosome specific to aortic tissue. 4. To examine aortic tissue using biochemistry including proteomics. 5. To establish the karyotype of fibroblasts with standard chromosome examination on 10 meta-phases as well as by fluorescent in situ hybridization (FISH) with probes covering the X and Y chromosome. Using the latter 200 meta-phases will be examined. 30 controls who did not die from aortic dissection or dilation will be recruited from The Department of Forensic Medicine at Aarhus University Hospital. The investigators will subject samples of aortic tissue from women undergoing prophylactic aortic surgery due to either Marfan syndrome or bicuspid aortic valve to the same panel of examinations (except karyotyping). Lastly the investigators will compare the results from the three groups (Turner syndrome, Marfan syndrome and Bicuspid aortic valve).

NCT ID: NCT01759316 Completed - Clinical trials for Respiratory Distress Syndrome

Heliox in Preterm Infants With Respiratory Distress Syndrome

Start date: December 2012
Phase: N/A
Study type: Interventional

Heliox can lower respiratory resistance, improve the oxygenation, reduce respiratory distress and lung injury caused by mechanical ventilation.

NCT ID: NCT01759108 Recruiting - Clinical trials for Improving Symptoms of Dry Mouth in Sjogren's Syndrome

Rebamipide AND Sjögren Syndrome

Start date: March 13, 2020
Phase: N/A
Study type: Interventional

Xerostomia is a major distressing symptom in Sjőgren's syndrome(SS). Preclinical and clinical studies have demonstrated an increase in saliva volume following rebamipide administration.We thus hypothesize that rebamipide may be efficacious in the treatment of dry mouth symptoms related to Sjőgren's syndrome.We will recruit SS patients in a randomized placebo-controlled trial for 12 weeks. The main outcome measure that will concern us is patient-assessed improvement of dry mouth symptoms and increase in salivary secretion Safety and efficacy was assessed at each visit.